How COVID-19 Is Driving Risks in the Illicit Benzodiazepines Market

According to research conducted by Express Scripts and cited by Harvard Medical School, prescriptions for medications to treat depression, anxiety or insomnia increased by 21 percent at the beginning of the COVID-19 pandemic in February. Prescriptions of anti-anxiety medications rose the most – by 34 percent over the month studied, with a week-on-week increase of almost 18 percent in the final week. These figures – and it’s highly likely that subsequent months saw further surges – reflect widespread mental health issues, driven by worries about the coronavirus, experiences of it, personal isolation and financial struggles.

Read more:

You May Also Like…


Submit a Comment

Your email address will not be published. Required fields are marked *